Literature DB >> 22989420

Dll4-Fc, an inhibitor of Dll4-notch signaling, suppresses liver metastasis of small cell lung cancer cells through the downregulation of the NF-κB activity.

Takuya Kuramoto1, Hisatsugu Goto, Atsushi Mitsuhashi, Sho Tabata, Hirohisa Ogawa, Hisanori Uehara, Atsuro Saijo, Soji Kakiuchi, Yoichi Maekawa, Koji Yasutomo, Masaki Hanibuchi, Shin-Ichi Akiyama, Saburo Sone, Yasuhiko Nishioka.   

Abstract

Notch signaling regulates cell-fate decisions during development and postnatal life. Little is known, however, about the role of Delta-like-4 (Dll4)-Notch signaling between cancer cells, or how this signaling affects cancer metastasis. We, therefore, assessed the role of Dll4-Notch signaling in cancer metastasis. We generated a soluble Dll4 fused to the IgG1 constant region (Dll4-Fc) that acts as a blocker of Dll4-Notch signaling and introduced it into human small cell lung cancer (SCLC) cell lines expressing either high levels (SBC-3 and H1048) or low levels (SBC-5) of Dll4. The effects of Dll4-Fc on metastasis of SCLC were evaluated using a mouse model. Although Dll4-Fc had no effect on the liver metastasis of SBC-5, the number of liver metastasis inoculated with SBC-3 and H1048 cells expressing Dll4-Fc was significantly lower than that injected with control cells. To study the molecular mechanisms of the effects of Dll4-Fc on liver metastasis, a PCR array analysis was conducted. Because the expression of NF-κB target genes was affected by Dll4-Fc, we conducted an electrophoretic mobility shift assay and observed that NF-κB activities, both with and without stimulation by TNF-α, were downregulated in Dll4-Fc-overexpressing SBC-3 and H1048 cells compared with control cells. Moreover, Dll4-Fc attenuates, at least in part, the classical and alternative NF-κB activation pathway by reducing Notch1 signaling. These results suggest that Dll4-Notch signaling in cancer cells plays a critical role in liver metastasis of SCLC by regulating NF-κB signaling.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22989420     DOI: 10.1158/1535-7163.MCT-12-0640

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  22 in total

1.  RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer.

Authors:  May Chammaa; Agnes Malysa; Carlos Redondo; Hyejeong Jang; Wei Chen; Gerold Bepler; Rodrigo Fernandez-Valdivia
Journal:  J Cell Physiol       Date:  2018-06-28       Impact factor: 6.384

Review 2.  Therapeutic modulation of Notch signalling--are we there yet?

Authors:  Emma R Andersson; Urban Lendahl
Journal:  Nat Rev Drug Discov       Date:  2014-05       Impact factor: 84.694

3.  Metastasis is impaired by endothelial-specific Dll4 loss-of-function through inhibition of epithelial-to-mesenchymal transition and reduction of cancer stem cells and circulating tumor cells.

Authors:  Liliana Mendonça; Alexandre Trindade; Catarina Carvalho; Jorge Correia; Marina Badenes; Joana Gigante; António Duarte
Journal:  Clin Exp Metastasis       Date:  2019-05-22       Impact factor: 5.150

4.  The association of intravascular stromal cells with prognosis in high-grade neuroendocrine carcinoma of the lung.

Authors:  Keigo Sekihara; Tomoyuki Hishida; Shinnosuke Ikemura; Koichi Saruwatari; Masahiro Morise; Takeshi Kuwata; Satoshi Fujii; Motohiro Kojima; Atsushi Ochiai; Kazuhito Funai; Keiju Aokage; Junji Yoshida; Masahiro Tsuboi; Genichiro Ishii
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-22       Impact factor: 4.553

5.  Brucine inhibits bone metastasis of breast cancer cells by suppressing Jagged1/Notch1 signaling pathways.

Authors:  Ke-Fei Hu; Xiang-Ying Kong; Mi-Cun Zhong; Hong-Ye Wan; Na Lin; Xiao-Hua Pei
Journal:  Chin J Integr Med       Date:  2016-12-29       Impact factor: 1.978

Review 6.  Signaling pathways and their potential therapeutic utility in esophageal squamous cell carcinoma.

Authors:  L K Kadian; M Arora; C P Prasad; R Pramanik; S S Chauhan
Journal:  Clin Transl Oncol       Date:  2022-01-06       Impact factor: 3.405

7.  In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight.

Authors:  James E Dahlman; Carmen Barnes; Omar Khan; Aude Thiriot; Siddharth Jhunjunwala; Taylor E Shaw; Yiping Xing; Hendrik B Sager; Gaurav Sahay; Lauren Speciner; Andrew Bader; Roman L Bogorad; Hao Yin; Tim Racie; Yizhou Dong; Shan Jiang; Danielle Seedorf; Apeksha Dave; Kamaljeet S Sandu; Matthew J Webber; Tatiana Novobrantseva; Vera M Ruda; Abigail K R Lytton-Jean; Christopher G Levins; Brian Kalish; Dayna K Mudge; Mario Perez; Ludmila Abezgauz; Partha Dutta; Lynelle Smith; Klaus Charisse; Mark W Kieran; Kevin Fitzgerald; Matthias Nahrendorf; Dganit Danino; Rubin M Tuder; Ulrich H von Andrian; Akin Akinc; Avi Schroeder; Dipak Panigrahy; Victor Kotelianski; Robert Langer; Daniel G Anderson
Journal:  Nat Nanotechnol       Date:  2014-05-11       Impact factor: 39.213

8.  Delta-like ligand 4 (Dll4) predicts the prognosis of clear cell renal cell carcinoma, and anti-Dll4 suppresses tumor growth in vivo.

Authors:  Guang-Hui Hu; Huan Liu; Peng Lai; Zhui-Feng Guo; Liang Xu; Xu-Dong Yao; Jun-Hua Zheng; Min Liu; Yun-Fei Xu
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

9.  Identifying specific Notch1 target proteins in lung carcinoma cells.

Authors:  Wael Abdo Hassan; Takaaki Ito
Journal:  Histol Histopathol       Date:  2020-10-23       Impact factor: 2.303

10.  Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.

Authors:  Dongheon Lee; Dongin Kim; Yu Bin Choi; Kyungjae Kang; Eun-Sil Sung; Jin-Hyung Ahn; Junseo Goo; Dong-Hoon Yeom; Hyun Sook Jang; Kyung Duk Moon; Sang Hoon Lee; Weon-Kyoo You
Journal:  MAbs       Date:  2016-04-06       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.